SVB Leerink Maintains Outperform on Zentalis Pharmaceuticals, Raises Price Target to $97
SVB Leerink analyst Andrew Berens maintains Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform and raises the price target from $89 to $97.
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours.
Notable Zentalis Pharmaceuticals Insider Trades $3.4M In Company Stock
Alexis Pinto, Chief Legal Officer at Zentalis Pharmaceuticals (NASDAQ:ZNTL), made a large buy and sell of company shares on October 25, according to a new SEC filing.
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 11)
Stifel Initiates Coverage On Zentalis Pharmaceuticals with Buy Rating, Announces Price Target of $84
Stifel analyst Bradley Canino initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Buy rating and announces Price Target of $84.
Oppenheimer Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating, Announces Price Target of $90
Oppenheimer analyst Matthew Biegler initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating and announces Price Target of $90.
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 15)
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 14)